Clinical trials: Therapy Effect
Healthy
Food-Effect on PK and PD of Single Oral Dose of CJ-12420 in Healthy Male Subjects
Primary: To evaluate food effect on the pharmacokinetics (PK) of a single oral dose of CJ-12420 in healthy male subjects. Secondary To explore food effect on the pharmacodynamics (PD) of single oral dose of CJ-12420 in healthy…
- Trial name
- NCT01830309
- Testing
- CJ-12420 200mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Pain, Osteoarthritis, Hip
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee…
- Conditions
- Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT00980798
- Testing
- OROS hydromorphone HCl
- Where
- 12 sites in Czechia, Romania and 2 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag International NV
Diabetic Foot Ulcer
Omega3 Wound Fish Skin Graft in the Treatment of DFUs
The purpose of this clinical evaluation is to collect patient outcome data on a commercially available 510K FDA-approved product that is derived from minimal processing of Atlantic cod fish skin: KerecisTM Omega3 Wound.
- Trial name
- NCT04133493
- Testing
- Kerecis Omega3 Wound, Fibracol
- Where
- 5 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kerecis Ltd.
Chronic Anal Fissure
An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects
This is an open label study. The study will consist of 1 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine, administered BID to subjects with chronic anal fissure.
- Trial name
- NCT00972907
- Testing
- Nifedipine coated suppositories
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- RDD Pharma Ltd
Corona Virus Infection
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
Primary Objective: To evaluate the effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by C-reactive protein (CRP) levels in adult patients hospitalized with severe coronavirus disease 2019…
- Trial name
- NCT04469621
- Testing
- SAR443122
- Where
- 10 sites in Argentina, Brazil and 3 more
- Volunteers
- 68 people
- Sponsor
- Sanofi
Biological Availability
Relative Bioavailability of Sorafenib Tablet for Oral Suspension
The primary objective of the study is to Investigate the relative bioavailability of sorafenib as 400 mg (4 x 100 mg) tablet for oral suspension formulation in comparison to 400 mg (2 x 200 mg) marketed tablet formulation.
- Trial name
- NCT02538393
- Testing
- Sorafenib (BAY43-9006) Film-coated tablet, Sorafenib (BAY43-9006) Oral suspension
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults
The primary objective is to determine the effect of repeated oral doses of eliglustat 150 mg twice daily (BID) on the pharmacokinetics (PK) of orally administered metoprolol 50 mg in healthy adults.
- Trial name
- NCT01659944
- Testing
- Eliglustat, Metoprolol
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Rheumatoid Arthritis
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid…
- Trial name
- NCT00279734
- Testing
- Tetanus + pnemococcal vaccines alone, Abatacept + vaccines
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Oral Contraceptive, Headache
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
The aim of the present study is to investigate whether women taking a new combined oral contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone withdrawal-associated symptoms such as pelvic pain or…
- Conditions
- Oral Contraceptive, Headache, Pelvic Pain
- Trial name
- NCT00778609
- Testing
- EV/DNG (Qlaira, BAY86-5027)
- Where
- 63 sites in Australia, Finland and 7 more
- Volunteers
- 449 people
- Sponsor
- Bayer
Irritable Bowel Syndrome, Crohn Disease
Effect of UGIR in Adults With Compromised Gut Function and Malabsorption
This study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption.
- Conditions
- Irritable Bowel Syndrome, Crohn Disease, Ulcerative Colitis, Celiac Disease
- Trial name
- NCT03011593
- Testing
- Nutrition Support Product
- Volunteers
- 18 people
- Sponsor
- Metagenics, Inc.
NSCLC
A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711
This is a phase I study to assess the effect of itraconazole and rifampicin on the pharmacokinetic parameters of BPI-7711 in Chinese healthy volunteers.
- Trial name
- NCT04135833
- Testing
- BPI-7711, Itraconazole, Rifampicin
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Beta Pharma, Inc.
Anaemia
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
This will be an open-label, randomized, parallel-group study in hemodialysis-dependent (HD) participants with anemia associated with chronic kidney disease (CKD), designed to compare the effects of daprodustat to epoetin alfa on…
- Trial name
- NCT03029247
- Testing
- Daprodustat, Epoetin alfa
- Where
- 11 sites in United States
- Volunteers
- 105 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.
- Trial name
- NCT05867147
- Testing
- Vanzacaftor, Moxifloxacin
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Multiple Myeloma
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
- Trial name
- NCT01183949
- Testing
- AT7519M, Bortezomib
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Astex Pharmaceuticals, Inc.
End Stage Renal Disease, Inflammation
Influence of the Vitamine E Coated Dialyzer on Inflammation and Anemia
Evaluation of the effect of a vitamin E coated high flux polysulfone dialyzer on the inflammatory state of patients' end stage renal disease and its clinical benefits in terms of anemia Objectives : To assess the benefits of a…
- Trial name
- EVIA (NCT03218865)
- Testing
- VIE high flux dialyzer, Leoceed H high flux dialyzer
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hemotech
Multiple Myeloma, Lymphoma, Non-Hodgkin's
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
This Phase 2 study was designed to assess the safety and hematological activity of AMD3100 (plerixafor) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who were predicted to be unable to mobilize ≥2*10^6…
- Trial name
- NCT00395967
- Testing
- G-CSF plus plerixafor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors.
- Conditions
- Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05468307
- Testing
- Membrane Bound Cytokine Modified TIL
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Juncell Therapeutics
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Male Contraception, Semen Volume
Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive
NLS-133-CLIN001 is a Phase 2a study designed to assess the safety, tolerability, and effects of NLS-133 (combination of two FDA-approved agents) compared to an active control (FDA-approved pharmacologic agent) or placebo on semen…
- Conditions
- Male Contraception, Semen Volume, Sperm Motility
- Trial name
- NCT07393334
- Testing
- NLS-133, Active Comparator #1
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Next Life Sciences
Biomarker
Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers
The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.
- Trial name
- NCT01159730
- Where
- United Kingdom
- Volunteers
- 320 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.